Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
The study aimed to assess the effectiveness and safety of L-ornithine-L-aspartate in the
 management of hepatic encephalopathy.
Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with
 minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance,
 or complain of cognitive symptoms, with poor health-related quality of life. This study will
 compare L-ornithine-L-aspartate with placebo for 60 days to assess the effectiveness, safety
 and health-related quality of life of this drug.
Inclusion Criteria:

 -  Cirrhosis and diagnosis of minimal hepatic encephalopathy using psychometric tests and
 critical flicker frequency

 Exclusion Criteria:

 -  Hepatic encephalopathy grade 1 to 4

 -  Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin)

 -  Psychoactive substance use within 72 hours